Global Medical REIT Announces Fourth Quarter and Year-End 2022 Financial Results

Rhea-AI Summary

Global Medical REIT (NYSE: GMRE) reported its financial results for 2022, revealing a 19.6% year-over-year increase in total revenue to $36.3 million in Q4 and $137.3 million for the year. Net income attributable to common stockholders for Q4 was $0.4 million ($0.01 per diluted share) compared to $3.8 million ($0.06 per diluted share) in the prior year. Full-year net income rose to $13.3 million ($0.20 per share) versus $11.8 million ($0.19 per share) previously. The company completed 14 acquisitions totaling $149 million. Rental revenue increased 19.7% to $36.3 million in Q4, despite total expenses climbing to $34.5 million.

Positive

• Total revenue increased by 19.6% year-over-year to $36.3 million in Q4 2022.
• Completed 14 acquisitions totaling $149 million during 2022.
• Net income for the full year rose to $13.3 million, up from $11.8 million year-over-year.
• Funds from Operations (FFO) for the full year was $64.0 million, a 10.6% increase compared to $58.2 million in 2021.

Negative

• Net income in Q4 2022 decreased significantly to $0.4 million from $3.8 million in Q4 2021.
• Total expenses for Q4 rose to $34.5 million, up from $25.9 million in the prior year.
• Interest expense in Q4 increased to $8.1 million from $4.8 million due to rising interest rates.

Acquires $149 Million in Medical Real Estate During 2022

BETHESDA, Md.--(BUSINESS WIRE)-- Global Medical REIT Inc. (NYSE: GMRE) (the “Company” or “GMRE”), a net-lease medical office real estate investment trust (REIT) that owns and acquires healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems, today announced financial results for the three and twelve months ended December 31, 2022 and other data.

Jeffrey M. Busch, Chairman, Chief Executive Officer and President stated, “We were able to navigate through a challenging period during 2022 by relying on the quality of our portfolio and the resilience of our tenant base. With the rise in interest rates, we prudently moderated our pace of growth, even as we locked in long term capital at very favorable rates. As we look to the future, we believe we are well-positioned to restart our acquisition activity as cap rate spreads return to an attractive level, and markets normalize. I would like to thank the entire team for their collective efforts and contributions to these results.”

Fourth Quarter 2022 Highlights

• Net income attributable to common stockholders was $0.4 million, or $0.01 per diluted share, as compared to $3.8 million, or $0.06 per diluted share, in the comparable prior year period.
• Funds from Operations (“FFO”) of $15.5 million, or $0.22 per share and unit, as compared to $15.6 million, or $0.23 per share and unit, in the comparable prior year period.
• Adjusted Funds from Operations (“AFFO”) of $16.5 million, or $0.24 per share and unit, as compared to $16.4 million, or $0.24 per share and unit, in the comparable prior year period.
• Increased total revenue 19.6% year-over-year to $36.3 million, primarily driven by the Company’s acquisition activity since the comparable prior year period.

Full Year 2022 Highlights

• Net income attributable to common stockholders was $13.3 million, or $0.20 per diluted share, as compared to $11.8 million, or $0.19 per diluted share, in the comparable prior year period.
• FFO of $64.0 million, or $0.92 per share and unit, as compared to $58.2 million, or $0.90 per share and unit, in the comparable prior year period.
• AFFO of $68.0 million, or $0.98 per share and unit, as compared to $61.4 million, or $0.95 per share and unit, in the comparable prior year period.
• Increased total revenue 18.4% year-over-year to $137.3 million, primarily driven by the Company’s acquisition activity since the comparable prior year period.
• Completed 14 acquisitions encompassing an aggregate 583,253 leasable square feet, for an aggregate purchase price of $148.9 million and a weighted average cap rate of 7.4%.
• Sold a medical office building located in Germantown, Tennessee, receiving gross proceeds of $17.9 million, resulting in a gain of $6.8 million.
• Amended credit facility to, among other things: (i) add a new $150 million term loan with a maturity date of February 1, 2028, (ii) extend the maturity of the revolver component of the credit facility from May 2025 to August 2026 with two six-month company-controlled extension options, and (iii) transition all LIBOR-based loans under the credit facility to SOFR-based loans.
• Entered into interest rate swaps with a notional value of $150 million that fix the SOFR component of the new term loan at 2.54% through its maturity.
• Generated $10.3 million in gross proceeds from ATM equity issuances at an average offering price of $17.15 per share.

Financial Results

Rental revenue for the fourth quarter 2022 increased 19.7% year-over-year to $36.3 million, reflecting the growth in the Company’s portfolio.

Total expenses for the fourth quarter were $34.5 million, compared to $25.9 million for the comparable prior year period, primarily reflecting higher interest, operating, depreciation, and amortization expenses due to the growth in the Company’s portfolio as well as rising interest rates in 2022.

Interest expense for the fourth quarter was $8.1 million, compared to $4.8 million for the comparable prior year period. This change was primarily the result of increased interest rates during 2022. The Company’s weighted average interest rate on its indebtedness increased from 2.88% in the fourth quarter of 2021 to 4.07% during the fourth quarter of 2022.

Net income attributable to common stockholders for the fourth quarter totaled $0.4 million, or $0.01 per diluted share, compared to $3.8 million, or $0.06 per diluted share, in the comparable prior year period.

The Company reported FFO of $15.5 million, or $0.22 per share and unit, and AFFO of $16.5 million, or $0.24 per share and unit, for the fourth quarter of 2022, which compares to FFO of $15.6 million, or $0.23 per share and unit, and AFFO of $16.4 million, or $0.24 per share and unit, in the comparable prior year period.

Investment Activity

For the full year 2022, the Company completed 14 acquisitions, encompassing an aggregate 583,253 leasable square feet, for an aggregate purchase price of $148.9 million at a weighted average cap rate of 7.4%.

In July 2022, the Company sold its medical office building located in Germantown, Tennessee receiving gross proceeds of $17.9 million, resulting in a gain on sale of $6.8 million.

As of February 28, 2023, the Company had one property under contract to acquire for a purchase price of $6.7 million. This property is currently in the due diligence period and is subject to various closing conditions. Accordingly, the transaction may not close on a timely basis or we may terminate the purchase contract and not close the transaction.

As of February 28, 2023, the Company had two properties under contract to sell for an aggregate sales price of $11.6 million. The buyers are currently in the due diligence periods and the transactions are subject to various closing conditions. Accordingly, the transactions may not close on a timely basis or the buyers may terminate the purchase agreements and not close the transactions.

Portfolio Update

As of December 31, 2022, the Company’s portfolio was 96.5% occupied and comprised of 4.9 million leasable square feet with an annualized base rent of $114.5 million. The weighted average lease term for the Company’s portfolio was 6.2 years with weighted average annual rental escalations of 2.1%, and the Company’s portfolio rent coverage ratio was 4.4 times as of December 31, 2022.

Balance Sheet and Capital

At December 31, 2022, total debt outstanding, including outstanding borrowings on the Company’s credit facility and notes payable (both net of unamortized debt issuance costs), was $694.1 million and the Company’s leverage was 47.6%, which was unchanged compared to September 30, 2022 and up from 43.0% at year-end 2021. As of December 31, 2022, the Company’s total debt carried a weighted average interest rate of 4.20% and a weighted average remaining term of 3.9 years. As of February 28, 2023, the Company’s unutilized borrowing capacity under the Company’s credit facility was $245.0 million.

The Company’s fixed debt totaled $558.1 million on a gross basis at December 31, 2022, representing 79% of its total debt, with a weighted average interest rate of 3.75% based on the Company’s interest rate swaps and at current leverage, with a weighted average maturity of 3.8 years. Due to the Company’s forward swap structures, the weighted average interest rate on fixed debt is expected to improve over the next few years. Weighted average interest rates on the Company’s fixed debt are expected to decrease to approximately 3.67% in 2023, 3.50% in 2024, and 3.43% in 2025, based on the Company’s current leverage.

During the year ended December 31, 2022, the Company issued 0.6 million shares of common stock through its ATM program at an average offering price of $17.15 per share, generating gross proceeds of $10.3 million. The Company did not issue any shares under its ATM program during the fourth quarter of 2022.

Dividends

On December 7, 2022, the Board of Directors (the “Board”) declared a $0.21 per share cash dividend to common stockholders and unitholders of record as of December 22, 2022, which was paid on January 9, 2023, representing the Company’s fourth quarter 2022 dividend payment. The Board also declared a $0.46875 per share cash dividend to holders of record as of January 15, 2023 of the Company’s Series A Preferred Stock, which was paid on January 31, 2023. This dividend represented the Company’s quarterly dividend on its Series A Preferred Stock for the period from October 31, 2022 through January 30, 2023.

2023 Annual Meeting

On February 23, 2023, the Board approved the meeting and record dates for the Company’s 2023 Annual Stockholders’ Meeting. The Meeting will be held on Wednesday, May 10, 2023. Stockholders of record as of March 15, 2023 will be eligible to vote at the Meeting.

SUPPLEMENTAL INFORMATION

Details regarding these results can be found in the Company’s supplemental financial package available on the Investor Relations section of the Company’s website at http://investors.globalmedicalreit.com/.

CONFERENCE CALL AND WEBCAST INFORMATION

The Company will host a live webcast and conference call on Wednesday, March 1, 2023 at 9:00 a.m. Eastern Time. The webcast is located on the “Investor Relations” section of the Company’s website at http://investors.globalmedicalreit.com/.

To Participate via Telephone:

Dial in at least five minutes prior to start time and reference Global Medical REIT Inc.
Domestic: 1-877-704-4453
International: 1-201-389-0920

Replay:

An audio replay of the conference call will be posted on the Company’s website.

NON‐GAAP FINANCIAL MEASURES

General

Management considers certain non-GAAP financial measures to be useful supplemental measures of the Company's operating performance. For the Company, non-GAAP measures consist of Earnings Before Interest, Taxes, Depreciation and Amortization for Real Estate (“EBITDAre” and “Adjusted EBITDAre”), FFO and AFFO. A non-GAAP financial measure is generally defined as one that purports to measure financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in accordance with GAAP. The Company reports non-GAAP financial measures because these measures are observed by management to also be among the most predominant measures used by the REIT industry and by industry analysts to evaluate REITs. For these reasons, management deems it appropriate to disclose and discuss these non-GAAP financial measures.

The non-GAAP financial measures presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income, as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's historical consolidated operating results, these measures should be examined in conjunction with net income and cash flows from operations as presented elsewhere herein.

FFO and AFFO

FFO and AFFO are non-GAAP financial measures within the meaning of the rules of the United States Securities and Exchange Commission (“SEC”). The Company considers FFO and AFFO to be important supplemental measures of its operating performance and believes FFO is frequently used by securities analysts, investors, and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results. In accordance with the National Association of Real Estate Investment Trusts’ (“NAREIT”) definition, FFO means net income or loss computed in accordance with GAAP before noncontrolling interests of holders of OP units and LTIP units, excluding gains (or losses) from sales of property and extraordinary items, less preferred stock dividends, plus real estate-related depreciation and amortization (excluding amortization of debt issuance costs and the amortization of above and below market leases), and after adjustments for unconsolidated partnerships and joint ventures. Because FFO excludes real estate-related depreciation and amortization (other than amortization of debt issuance costs and above and below market lease amortization expense), the Company believes that FFO provides a performance measure that, when compared period-over-period, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from the closest GAAP measurement, net income or loss.

AFFO is a non-GAAP measure used by many investors and analysts to measure a real estate company’s operating performance by removing the effect of items that do not reflect ongoing property operations. Management calculates AFFO by modifying the NAREIT computation of FFO by adjusting it for certain cash and non-cash items and certain recurring and non-recurring items. For the Company these items include: (a) recurring acquisition and disposition costs, (b) loss on the extinguishment of debt, (c) recurring straight line deferred rental revenue, (d) recurring stock-based compensation expense, (e) recurring amortization of above and below market leases, (f) recurring amortization of debt issuance costs, (g) recurring lease commissions, and (h) other items.

Management believes that reporting AFFO in addition to FFO is a useful supplemental measure for the investment community to use when evaluating the operating performance of the Company on a comparative basis.

EBITDAre and Adjusted EBITDAre

We calculate EBITDAre in accordance with standards established by NAREIT and define EBITDAre as net income or loss computed in accordance with GAAP plus depreciation and amortization, interest expense, gain or loss on the sale of investment properties, and impairment loss, as applicable.

We define Adjusted EBITDAre as EBITDAre plus non-cash stock compensation expense, non-cash intangible amortization related to above and below market leases, preacquisition expense and other normalizing items. Management considers EBITDAre and Adjusted EBITDAre important measures because they provide additional information to allow management, investors, and our current and potential creditors to evaluate and compare our core operating results and our ability to service debt.

RENT COVERAGE RATIO

For purposes of calculating our portfolio weighted-average EBITDARM coverage ratio (“Rent Coverage Ratio”), we excluded credit-rated tenants or their subsidiaries for which financial statements were either not available or not sufficiently detailed. These ratios are based on latest available information only. Most tenant financial statements are unaudited and we have not independently verified any tenant financial information (audited or unaudited) and, therefore, we cannot assure you that such information is accurate or complete. Certain other tenants (approximately 16% of our portfolio) are excluded from the calculation due to (i) lack of available financial information or (ii) small tenant size. Additionally, included within 16% of non-reporting tenants is Pipeline Healthcare, LLC, which filed for Chapter 11 bankruptcy protection in October of 2022. Additionally, our Rent Coverage Ratio adds back physician distributions and compensation. Management believes all adjustments are reasonable and necessary.

ANNUALIZED BASE RENT

Annualized base rent represents monthly base rent for December 2022, multiplied by 12 (or base rent net of annualized expenses for properties with gross leases). Accordingly, this methodology produces an annualized amount as of a point in time but does not take into account future (i) contractual rental rate increases, (ii) leasing activity or (iii) lease expirations. Additionally, leases that are accounted for on a cash-collected basis are not included in annualized base rent.

CAPITALIZATION RATE

The capitalization rate (“cap rate”) for an acquisition is calculated by dividing current Annualized Base Rent by contractual purchase price. For the portfolio capitalization rate, certain adjustments, including for subsequent capital invested, are made to the contractual purchase price.

FORWARD-LOOKING STATEMENTS

Certain statements contained herein may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and it is the Company’s intent that any such statements be protected by the safe harbor created thereby. These forward-looking statements are identified by their use of terms and phrases such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "plan," "predict," "project," "will," "continue" and other similar terms and phrases, including references to assumptions and forecasts of future results. Except for historical information, the statements set forth herein including, but not limited to, any statements regarding our earnings, our liquidity, our tenants’ ability to pay rent to us, expected financial performance (including future cash flows associated with new tenants or the expansion of current properties), future dividends or other financial items; any other statements concerning our plans, strategies, objectives and expectations for future operations and future portfolio occupancy rates, our pipeline of acquisition opportunities and expected acquisition activity, including the timing and/or successful completion of any acquisitions and expected rent receipts on these properties, our expected disposition activity, including the timing and/or successful completion of any dispositions and the expected use of proceeds therefrom, and any statements regarding future economic conditions or performance are forward-looking statements. These forward-looking statements are based on our current expectations, estimates and assumptions and are subject to certain risks and uncertainties. Although the Company believes that the expectations, estimates and assumptions reflected in its forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of the Company’s forward-looking statements. Additional information concerning us and our business, including additional factors that could materially and adversely affect our financial results, include, without limitation, the risks described under Part I, Item 1A - Risk Factors, in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, and in our other filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements. The Company does not intend, and undertakes no obligation, to update any forward-looking statement.

GLOBAL MEDICAL REIT INC. Condensed Consolidated Balance Sheets (unaudited, and in thousands, except par values)
		As of December 31,
		2022				2021
Assets
Investment in real estate:
Land		$	168,308			$	152,060
Building			1,079,781				985,091
Site improvements			22,024				19,021
Tenant improvements			65,987				58,900
Acquired lease intangible assets			148,077				127,931
			1,484,177				1,343,003
Less: accumulated depreciation and amortization			(198,218	)			(143,255	)
Investment in real estate, net			1,285,959				1,199,748
Cash and cash equivalents			4,016				7,213
Restricted cash			10,439				5,546
Tenant receivables, net			8,040				6,070
Due from related parties			200				163
Escrow deposits			7,833				5,957
Deferred assets			29,616				25,417
Derivative asset			34,705				1,236
Goodwill			5,903				5,903
Other assets			6,550				6,232
Total assets		$	1,393,261			$	1,263,485
Liabilities and Equity
Liabilities:
Credit Facility, net of unamortized debt issuance costs of $9,253 and $8,033 at December 31, 2022 and December 31, 2021, respectively		$	636,447			$	514,567
Notes payable, net of unamortized debt issuance costs of $452 and $607 at December 31, 2022 and December 31, 2021, respectively			57,672				57,162
Accounts payable and accrued expenses			13,819				10,344
Dividends payable			15,821				15,668
Security deposits			5,461				4,540
Derivative liability			—				7,790
Other liabilities			7,363				7,709
Acquired lease intangible liability, net			7,613				8,128
Total liabilities			744,196				625,908
Commitments and Contingencies
Equity:
Preferred stock, $0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at December 31, 2022 and December 31, 2021, respectively (liquidation preference of $77,625 at December 31, 2022 and December 31, 2021, respectively)			74,959				74,959
Common stock, $0.001 par value, 500,000 shares authorized; 65,518 shares and 64,880 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively			66				65
Additional paid-in capital			721,991				711,414
Accumulated deficit			(198,706	)			(157,017	)
Accumulated other comprehensive income (loss)			34,674				(6,636	)
Total Global Medical REIT Inc. stockholders' equity			632,984				622,785
Noncontrolling interest			16,081				14,792
Total equity			649,065				637,577
Total liabilities and equity		$	1,393,261			$	1,263,485

GLOBAL MEDICAL REIT INC. Condensed Consolidated Statements of Operations (unaudited, and in thousands, except per share amounts)
		Three Months Ended December 31,								Twelve Months Ended December 31,
		2022				2021				2022				2021
Revenue
Rental revenue		$	36,290			$	30,312			$	137,167			$	115,804
Other income			16				32				116				132
Total revenue			36,306				30,344				137,283				115,936
Expenses
General and administrative			4,051				3,934				16,545				16,453
Operating expenses			7,138				4,525				25,188				15,488
Depreciation expense			10,580				9,046				40,008				33,825
Amortization expense			4,513				3,607				16,715				13,050
Interest expense			8,064				4,809				25,230				19,696
Preacquisition expense			112				5				354				151
Total expenses			34,458				25,926				124,040				98,663
Income before gain on sale of investment property			1,848				4,418				13,243				17,273
Gain on sale of investment property			—				1,069				6,753				1,069
Net income		$	1,848			$	5,487			$	19,996			$	18,342
Less: Preferred stock dividends			(1,455	)			(1,455	)			(5,822	)			(5,822	)
Less: Net income attributable to noncontrolling interest			(24	)			(228	)			(854	)			(720	)
Net income attributable to common stockholders		$	369			$	3,804			$	13,320			$	11,800
Net income attributable to common stockholders per share – basic and diluted		$	0.01			$	0.06			$	0.20			$	0.19
Weighted average shares outstanding – basic and diluted			65,518				64,326				65,462				60,640

Global Medical REIT Inc. Reconciliation of Net Income to FFO and AFFO (unaudited, and in thousands, except per share and unit amounts)
		Three Months Ended December 31,								Twelve Months Ended December 31,
		2022				2021				2022				2021
Net income		$	1,848			$	5,487			$	19,996			$	18,342
Less: Preferred stock dividends			(1,455	)			(1,455	)			(5,822	)			(5,822	)
Depreciation and amortization expense			15,064				12,624				56,611				46,764
Gain on sale of investment property			—				(1,069	)			(6,753	)			(1,069	)
FFO		$	15,457			$	15,587			$	64,032			$	58,215
Amortization of above market leases, net			292				202				1,027				520
Straight line deferred rental revenue			(1,006	)			(1,170	)			(4,251	)			(5,317	)
Stock-based compensation expense			1,066				1,242				4,681				5,810
Amortization of debt issuance costs and other			601				514				2,201				1,982
Preacquisition expense			112				5				354				151
AFFO		$	16,522			$	16,380			$	68,044			$	61,361
Net income attributable to common stockholders per share – basic and diluted		$	0.01			$	0.06			$	0.20			$	0.19
FFO per share and unit		$	0.22			$	0.23			$	0.92			$	0.90
AFFO per share and unit		$	0.24			$	0.24			$	0.98			$	0.95
Weighted Average Shares and Units Outstanding – basic and diluted			69,725				68,214				69,662				64,548
Weighted Average Shares and Units Outstanding:
Weighted Average Common Shares			65,518				64,326				65,462				60,640
Weighted Average OP Units			1,668				1,702				1,669				1,732
Weighted Average LTIP Units			2,539				2,186				2,531				2,176
Weighted Average Shares and Units Outstanding – basic and diluted			69,725				68,214				69,662				64,548

Global Medical REIT Inc. Reconciliation of Net Income to EBITDAre and Adjusted EBITDAre (unaudited, and in thousands)
		Three Months Ended December 31,							Twelve Months Ended December 31,
		2022			2021				2022				2021
Net income		$	1,848		$	5,487			$	19,996			$	18,342
Interest expense			8,064			4,809				25,230				19,696
Depreciation and amortization expense			15,093			12,653				56,723				46,875
Gain on sale of investment property			—			(1,069	)			(6,753	)			(1,069	)
EBITDAre		$	25,005		$	21,880			$	95,196			$	83,844
Stock-based compensation expense			1,066			1,242				4,681				5,810
Amortization of above market leases, net			292			202				1,027				520
Preacquisition expense			112			5				354				151
Adjusted EBITDAre		$	26,475		$	23,329			$	101,258			$	90,325

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228006365/en/

Investor Relations:

Stephen Swett

stephen.swett@icrinc.com

203.682.8377

Source: Global Medical REIT Inc.

FAQ

What were GMRE's total revenues for the fourth quarter of 2022?

GMRE reported total revenues of $36.3 million for Q4 2022, a 19.6% increase year-over-year.

How much net income did GMRE report for the full year of 2022?

GMRE reported a net income of $13.3 million for the full year 2022, compared to $11.8 million in 2021.

What acquisitions did GMRE complete in 2022?

In 2022, GMRE completed 14 acquisitions totaling $149 million.

What is GMRE's Funds from Operations (FFO) for 2022?

GMRE's FFO for the full year 2022 was $64.0 million, representing a 10.6% increase from the previous year.